Needham Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $130
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and sets a price target of $130.
July 22, 2024 | 9:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has initiated coverage on Axsome Therapeutics with a Buy rating and a price target of $130.
The initiation of coverage with a Buy rating and a high price target of $130 by a reputable analyst is likely to positively impact the stock price of Axsome Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100